Loading company
Spyre Therapeutics, Inc.
SYRE · Nasdaq · ·
Next earnings: November 3, 2026
$84.70-1.3%Sep 29 close
- 1M
- -4.3%
- 6M
- +73.2%
- 1Y
- +414.6%
- 5Y
- -56.7%
SYRE · Nasdaq · ·
Next earnings: November 3, 2026
$84.70-1.3%Sep 29 close
Spyre Therapeutics, Inc. is scheduled to report next on November 3, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2024, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2024 | 3 months toDec 31, 2023 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$36.2M | -$36.7M | +1.41% |
| Profit per share | -$0.35 | -$0.86 | +59.16% |
| Free Cash Flow | -$31M | -$26.3M | -18.01% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Following encouraging Phase 2 results from both SPY001 and SPY002, as well as competitor results validating the promise of combination therapy, the case for our approach in IBD has strengthened considerably. We believe our three investigational combinations have the potential to deliver efficacy, safety, and convenience beyond what is achievable with today’s therapies,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Spyre Therapeutics, Inc.’s Item 2.02 8-K filed August 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Spyre Therapeutics, Inc. has no earnings call transcript available.